The invention relates to a maternal-fetal blood group incompatibility treatment adsorber in the medical field. The maternal-fetal blood group incompatibility treatment adsorber is characterized in that Rh negative B cells and myeloma cells are solvated into B cell hybridoma cells to prepare Rh antibodies, wherein the Rh negative B cells are immortalized with the EB virus and sensitized with Rh positive red blood cells and can generate Rh antibodies; the Rh antibodies serve as an antigen immune animal to prepare anti-Rh antibodies; the anti-Rh antibodies are prepared into the 1:700, 1:500, 1:300, 1:200 and 1:100 titer gradient with 1.0% agarose, 8-10 ml of the anti-Rh antibodies are taken in sequence from high titer to low tilter and added into a cylindrical vessel made of a high polymer material, and gel forms layered distribution from top to bottom from low antibody tilter to high antibody tilter; when plasma flows through the treatment adsorber, the Rh antibodies are immobilized in the anti-Rh antibodies in the gel for layered binding, macromolecular harmful substances generated by damaged red cells are intercepted by micropores of the gel, the plasma with the Rh antibodies and the pathogenic substances removed is transfused back into the body, and thus the maternal-fetal blood group incompatibility haemolytic disease caused when too many Rh antibodies of a pregnant woman exist and enter the blood of a fetus is avoided.